CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Large-Cap Injectable-Focused Pharma Company Gains USFDA Nod for Key Pain Management Drug

With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent.

DSIJ Intelligence 0 182 Article rating: 5.0

With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent.

Gland Pharma Ltd.

Maintaining A Healthy Edge

Ninad Ramdasi 0 1418 Article rating: 3.8

With its particular acclaim for sterile injectables, oncology and ophthalmic products, the company has begun to reinforce its position on the international stage by venturing into markets like Saudi Arabia, Singapore, Israel and CIS regions.

These quality mid-cap stocks have fallen more than 10 per cent in the month of December!

Amid the heavy sell off, many quality midcaps, which have proven to be wealth creators for the investors in the past, have witnessed correction and are trading at low PE

DSIJ Intelligence 0 5866 Article rating: 3.8

With times like these, investors shouldn’t panic and keep a close eye on the fundamentally strong companies,

RSS

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR